ANRO - NYSE
Alto Neuroscience, Inc.
$19.42
+3.8%Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company that engages in the psychiatry drug development business. The company develops ALTO-100 for the treatment of patients with major depressive disorder (MDD) and post-traumatic stress disorder; ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties to treat patients with MDD; and ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor for the treatment of cognitive impairment associated with schizophrenia. It also develops ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist to treat patients with MDD and higher levels of anhedonia, and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor for the treatment of MDD. In addition, the company develops novel pharmacodynamically synergistic combinations and an AI-enabled biomarker platform that combine sources of information on patients brain activity and behavior to identify patients to respond to novel product candidates. Alto Neuroscience, Inc. was incorporated in 2019 and is based in Los Altos, California.
At a Glance
Live Snapshotanro
Total Assets
Last Annual Value
184.69M
3-Year CAGR
54%
5-Year CAGR
45%
10-Year CAGR
20%
Alto Neuroscience, Inc. Competitors Analysis of Total Assets
| Company | Total Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Alto Neuroscience, Inc. NYSE:ANRO | 184.69M | 28.7% | 45.0% | N/A | |
 Korro Bio, Inc. NASDAQ:KRRO | 113.51M | -20.0% | -9.3% | N/A | |
 Actuate Therapeutics Inc NASDAQ:ACTU | 14.04M | 67.3% | N/A | N/A | |
 Applied Therapeutics, Inc. NASDAQ:APLT | 86.69M | 16.5% | -0.7% | N/A | |
 C4 Therapeutics, Inc. NASDAQ:CCCC | 359.07M | -1.6% | -6.7% | N/A | |
 Cardiff Oncology, Inc. NASDAQ:CRDF | 61.88M | -8.8% | -16.2% | 3.5% | |
 Nuvectis Pharma, Inc. NASDAQ:NVCT | 31.71M | 18.2% | 36.6% | N/A | |
 PepGen Inc. NASDAQ:PEPG | 173.91M | 6.7% | 3.9% | N/A | |
 VistaGen Therapeutics, Inc. NASDAQ:VTGN | 84.34M | 58.7% | -4.9% | 56.0% | |
276.64M | 28.5% | 31.4% | N/A | ||
 Aldeyra Therapeutics, Inc. NASDAQ:ALDX | 72.06M | -21.4% | -20.9% | 11.1% |
Alto Neuroscience, Inc. Fair Value Envelope
Related Guides
Continue your ANRO research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.